

P0052-2025

בחינת סיום התמחות חלק א' + ב' – ראומטולוגיה מסלול ילדים

שלב א':

המבחן מורכב מ-100 שאלות, חלקן שאלות משותפות לראומטולוגיה מבוגרים וחלקן שאלות נפרדות לראומטולוגיה ילדים.

השאלות המשותפות יותאמו לילדים ולסילבוס שלנו והם יתרכזו בנושאים המשותפים לראומטולוגיה ילדים ומבוגרים כמו תרופות, בדיקות מעבדה, אימונולוגיה ומחלות משותפות. בגלל ההתאמות יתכנו מעט הבדלים לשאלות וההיגדים של ראומטולוגיה מבוגרים. ציון המעבר הוא 65.

סילבוס:

1. המהדורה האחרונה של Cassidy (מהדורה 8)
 2. מאמרים נבחרים לפי רשימת מאמרים מצורפת.
- אם יש "מחלוקת" בין המקורות שונים בסילבוס, הגרסה של Cassidy תקבע את התשובה הנכונה.

שלב ב':

הבחינה תורכב מ-4 מקרים "גדולים" – מדובר במקרה קליני שיכול להתפתח לכיוונים שונים ויכלול דיון נרחב. יכללו במקרים הקליניים גם שאלות מהספרות העדכנית ופתרון תמונות. הציונים הם עובר בהצטיינות, עובר ונכשל. **הסילבוס זהה לשלב א'.**

רשימת ספרות מחייבת לבחינת סיום התמחות חלק א' + ב' - ראומטולוגיה מסלול ילדים

Nature Review Rheumatology

1. Vascular **Behçet** syndrome: from pathogenesis to treatment. Bettiol A et al; Nat Rev Rheumatol. 2023 Feb; 19(2): 111-126 PMID: 36544027.
2. Juvenile idiopathic **inflammatory myositis**: an update on pathophysiology and clinical care. Charalampia Papadopoulou. Nat Rev Rheumatol 2023 . Jun; 19(6): 343-362 PMID: 37188756
3. **Relapsing polychondritis**: clinical updates and new differential diagnoses. Philippe Mertz et al; Nat Rev Rheumatol 2024 Jun; 20(6): 347-360. PMID: 38698240
4. Rethinking **antiphospholipid syndrome** to guide future management and research. Knight JS et al; Nat Rev Rheumatol. 2024 Jun; 20(6): 377-388. PMID: 38702511
5. **CAR T cell therapy for children with rheumatic disease: the time is now** Wobma, H., Ardoin, S.P., Bonifant, C.L. *et al. Nat Rev Rheumatol* **21**, 494–506 (2025). PMID 40603629. Review
6. **Advances in the treatment of ANCA-associated vasculitis**. Trivioli, G., Casal Moura, M., Kronbichler, A. *et al. Nat Rev Rheumatol* **21**, 396–413 (2025). PMID 40473820
7. **The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis**. Gül, A., Aksentijevich, I., Brogan, P. *et al. Nat Rev Rheumatol* **21**, 414–425 (2025). PMID 40369133
8. **IgG4-related disease and other fibro-inflammatory conditions**. Peyronel, F., Della-Torre, E., Maritati, F. *et al. Nat Rev Rheumatol* **21**, 275–290 (2025). PMID 40195520
9. **HLA-B27** and spondyloarthritis: at the crossroads of innate and adaptive immunity. Navid, F., Chen, L., Bowness, P. *et al. Nat Rev Rheumatol* **21**, 77–87 (2025) PMID 39623156

10. Emerging concepts and treatments in autoinflammatory interferonopathies and **monogenic systemic lupus erythematosus**. Goldbach-Mansky, R., Alehashemi, S. & de Jesus, A.A. *Nat Rev Rheumatol* **21**, 22–45 (2025) PMID 39623155
11. An update on autoantibodies in the **idiopathic inflammatory myopathies**. Allameen, N.A., Ramos-Lisbona, A.I., Wedderburn, L.R. *et al. Nat Rev Rheumatol* **21**, 46–62 (2025). PMID 39609638
12. The management of adult and paediatric **uveitis** for rheumatologists. Clarke, S.L.N., Maghsoudlou, P., Guly, C.M. *et al. Nat Rev Rheumatol* **20**, 795–808 (2024) PMID 39506056
13. **Platelets in Kawasaki** disease: mediators of vascular inflammation. Noval Rivas, M., Kocatürk, B., Franklin, B.S. *et al. Nat Rev Rheumatol* **20**, 459–472 (2024). PMID 38886559

New England Journal of Medicine

1. **Juvenile Idiopathic Arthritis**. Sandborg CI, Schulert GS, Kimura Y. N Engl J Med..PMID: 4063295
2. Efficacy and Safety of **Obinutuzumab in Active Lupus Nephritis**. Furie RA, et al. N Engl J Med. 2025. PMID: 39927615 Clinical Trial
3. Drug Reaction with **Eosinophilia** and Systemic Symptoms. Kroshinsky D, Cardones ARG, Blumenthal KG.N Engl J Med. 2024 Dec .PMID: 39665653 Review.
4. Primary **Central Nervous System Vasculitis**. Salvarani C, Hunder GG, Brown RD Jr.N Engl J Med. 2024 Sep PMID: 39292929 Review

The Lancet Rheumatology

1. Effects of **tapering** conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (**ARCTIC REWIND**): 3-year results from an open-label, randomised controlled, non-inferiority trial. Kjorholt KE et al; Lancet Rheumatol. 2024 May. PMID: 38583450
2. ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Laurent Arnaud ET AL; 2025 Jul; PMID 40418946
3. Allogeneic haematopoietic stem-cell transplantation for children with refractory systemic juvenile idiopathic arthritis and associated lung disease: outcomes from an international, retrospective cohort study. Matt MG, et al. Lancet Rheumatol. 2025. PMID: 39718183
4. Arthritis complicating **inflammatory bowel disease**- the future is now. Song K, Satsangi J, Coates LC. Lancet Rheumatol 2024 Nov PMID: 39032495

Annals of Rheumatic Diseases

1. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Y Katsumoto; 2024 Jul; PMID 38423757
2. Treatment of early oligoarticular psoriatic arthritis with **apremilast**: primary outcomes at week 16 from the FOREMOST randomised controlled trial Laure Gossec et al; 2024 Oct ; PMID 39164067
3. Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (**CNO**) in adults. Elizabeth Winter et al; 2025 Feb, PMID: 39919892

4. Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases – a systematic literature review informing the 2024 update of an international expert consensus statement Victoria Konzett et al; 2025 May; PMID: 39934016
5. Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls. Zahi Touma et al; 2025 Feb; PMID: 39894690
6. Safety of colchicine on fertility, pregnancy, and lactation: a systematic review and meta-analysis informing the EULAR/PReS recommendations for familial Mediterranean fever. Teresa Otón et al; 2025 Jun; PMID: 40023732
7. Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force Angelo Ravelli et al; 2025 Jul; PMID: 40410052

Rheumatology

1. **Anti-rituximab antibodies** demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus. Chris Wincup and others. Rheumatology, July 2023, PMID 36370065
2. **Biologics with or without methotrexate in treatment of polyarticular juvenile idiopathic** arthritis: effectiveness, safety and drug survival. Franz Thiele and others. Rheumatology, June 2023, PMID 36222562
3. **Infantile Takayasu**: clinical features and long-term outcome. Miller-Barmak A et al; Rheumatology (Oxford). 2023 Sep. PMID: 36495199
4. Addressing the unmet needs of **transitional care** in juvenile idiopathic arthritis. Şahin N, et al. Rheumatology (Oxford). 2024. PMID: 37774006
5. **Colchicine**: the good, the bad, the ugly and how to minimize the risks. Stamp LK, et al. Rheumatology (Oxford). 2024 Apr; PMID: 38019947
6. Renal **relapse** in children and adolescents with childhood-onset **lupus nephritis**: a 20-year study. Chan EY, et al. Rheumatology (Oxford). 2024 Apr. PMID 37632777

7. Impact of serological activity on flare following clinically inactive disease and remission in childhood-onset systemic lupus erythematosus. Hakan Kisaoglu et al; Rheumatology (Oxford) 2024 Sep ,PMID: 38048608
8. Validation of the PEDiatric Behcet's Disease classification criteria: an evidence-based approach. Matucci-Cerinic C et al; Rheumatology (Oxford). 2024 Dec. PMID: 37991850
9. Could tocilizumab be used in familial Mediterranean fever? A systematic review. Mertz P et al; Rheumatology (Oxford). 2025 Jan 1; PMID: 38950176
10. British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with **Behcets** 2024. Murphy R et al; Rheumatology (Oxford). 2025 Jan ,PMID: 39253811
11. British Society for Rheumatology guideline on management of adult and juvenile onset **Sjogren** disease. Price EJ et al; Rheumatology (Oxford). 2025 Feb. PMID: 38621708
12. Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews. Moore A et al; Rheumatology (Oxford). 2025 May .PMID: 39705187
13. Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of **axial spondyloarthritis** with biologic and targeted synthetic DMARDs. Zhao SS et al; Rheumatology (Oxford). 2025 Jun. PMID: 40199508

Current Opinion in Rheumatology

1. Practical management strategies for **benign hypermobility syndromes**. Minhas, Deeba. 33(3): 249-254, May 2021; PMID: 33741806
2. Practical management of **Raynaud's phenomenon** - a primer for practicing physicians. Ramahi et al; Curr Opin Rheumatol. 2022 Jul , PMID: 35699336
3. Update on treatment responses and outcome measure development in **chronic nonbacterial osteomyelitis**. Ramachandran, ferguson polly sept 2023 PMID 37433220
4. **Treatment of juvenile localized scleroderma**: current recommendations, response factors, and potential alternative treatments Suzanne C. Li et al; sept 2022. PMID 35880663
5. Quo vadis **reactive arthritis**? Zeidler, Henning; Hudson, Alan P., July 2022 PMID: 35699331
6. Vasculitis and the **NLRP3** inflammasome. Hamzaoui, Kamel a et al; Curr Opin Rheumatol 2024 Jan. PMID 37582052
7. **Vaccination updates** and special considerations for systemic **lupus** erythematosus patients. Law et al; Curr Opin Rheumatol. 2024 Mar; PMID 37976046
8. Rheumatologic **immune checkpoint inhibitor**-related adverse events. Defoe M et al; Curr Opin Rheumatol. 2023 May. PMID: 36912045
9. **Calcinosis** in dermatomyositis. Davuluri S et al; Curr Opin Rheumatol. 2024 Nov, PMID: 39120537
10. **Urticarial vasculitis**. Ergun T. Curr Opin Rheumatol. 2025 Jan. PMID: 39600289
11. **Pediatric antiphospholipid** syndrome: expanding our understanding of antiphospholipid syndrome in children. Lewis K et al; Curr Opin Rheumatol. 2025 May, PMID: 39981610
12. Update on **streptococcal-associated rheumatic disease**. Shemesh S, Haviv R, Uziel Y. Curr Opin Rheumatol. 2025 Sep , PMID: 40462695

Arthritis Care & Research

1. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of **Polyarteritis Nodosa**. Chung SA et al; Arthritis Care Res (Hoboken). 2021 Aug; PMID: 34235889
2. Musculoskeletal **Ultrasound** and the Assessment of Disease Activity in Juvenile Idiopathic Arthritis. Patricia Vega-Fernandez, 18 December 2022. PMID 36530040
3. Disease course, treatments, and outcomes of children with systemic juvenile idiopathic arthritis associated lung disease (**SJIA-LD**). Yannan Huang et al; Arthritis Care Res 2023 Sep 10. PMID: 37691306
4. Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Mannion ML et al; Arthritis Care Res (Hoboken). 2024 Aug; PMID: 3855694

Arthritis and Rheumatology

1. The Conundrum of **Lung Disease** and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis. Binstadt BA, 2022 Jul; PMID: 35413159
2. **Complement**- a review, Paul Monach Arthritis Rheumatol 2024 Jan; PMID: 37551641
3. Therapeutic **Drug Monitoring**: A Tool to Optimize Treatment of Inflammatory Joint Diseases, Silje W. Syversen; Arthritis Rheumatol 2024 May, PMID 37984460
4. Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis. Weiss PF et al; Arthritis Rheumatol. 2024 Dec; PMID: 39039899

5. Understanding the Role of **Type I Interferons** in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics. Hile GA et al; Arthritis Rheumatol. 2025 Jan. PMID: 39262215
6. **Emapalumab** Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Chandrakasan S et al; Arthritis Rheumatol. 2025 Feb; PMID: 39245963
7. **Macrophage Activation Syndrome**. Nigrovic PA. Arthritis Rheumatol. 2025 Apr; PMID: 39491365
8. Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology. Noaiseh G et al; Arthritis Rheumatol. 2025 Apr; PMID: 39489692
9. Clinical, Immunologic, and Genetic Characteristics in Patients With Syndrome of Undifferentiated Recurrent Fevers. Macaraeg M et al; Arthritis Rheumatol. 2025 May; PMID: 39622767
10. Evaluating Renal Disease in Pediatric-Onset Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Disease Course, Outcomes, and Predictors of Outcome. Toor KK et al; Arthritis Rheumatol. 2025 May; PMID: 39624015

Pediatric Rheumatology

1. Increasing the **etanercept dose** in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomized clinical trial. van Dijk et al; Pediatr Rheumatol **22**, 53 (2024). PMID 38730442
2. Rheumatological complaints in **H syndrome**: from inflammatory profiling to target treatment in a case study. Tesser, A et al; Pediatr Rheumatol **22**, 21 (2024). PMID: 38263041
3. **Protracted febrile myalgia** syndrome in children with familial Mediterranean fever - systematic review and a case report. Hospach T et al. Pediatr Rheumatol Online J. 2024 Sep, PMID: 39256780

Others:

1. Advances in Imaging and Targeted Therapies for **Recurrent Pericarditis**: A Review. Kumar S et al , JAMA Cardiol. 2022 Sep. PMID: 35976625.
2. Evaluation, Treatment, and Outcomes of Viral and **Autoimmune Encephalitis** in Children. Joshua A Vova 1, Robyn A Howarth 2. Pediatr Clin North Am Jun; 2023; PMID: 37121635
3. Diagnostic criteria for **autoimmune encephalitis**: utility and pitfalls for antibody-negative disease. Dalmau J, Graus F. Lancet Neurol. 2023 Jun; PMID: 3721010
4. Evaluation and Management of **Deficiency of Adenosine Deaminase 2**: An International Consensus Statement. Lee PY et al; JAMA Netw Open. 2023 May. PMID: 37256629
5. Pediatric joint **hypermobility**: a diagnostic framework and narrative review. Tofts LJ et al; Orphanet J Rare Dis. 2023 May. PMID: 37143135
6. Intravenous Immunoglobulin Alone for Coronary Artery Lesion Treatment of Kawasaki Disease: A Randomized Clinical Trial. Kuo HC, et al. JAMA Netw Open. 2025 Apr. PMID: 40178858

ACR Guidelines:

1. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of **Juvenile Idiopathic Arthritis**: Therapeutic Approaches for Non-Systemic **Polyarthritis, Sacroiliitis, and Entesitis**. Arthritis Care & Research. 2019. PMID: 31021537
2. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of **Kawasaki Disease**. Gorelik M. Arthritis Rheumatol. 2022 Mar 7. PMID: 35257501.
3. 2021 American College of Rheumatology Guideline for the Treatment of **Juvenile Idiopathic Arthritis**: Therapeutic Approaches for **Oligoarthritis**,

Temporomandibular Joint Arthritis, and

Systemic Juvenile Idiopathic Arthritis. Onel KB, Horton DB

PMID: 35233993

4. 2021 American College of Rheumatology Guideline for the Treatment of **Juvenile Idiopathic Arthritis**: Recommendations for **Nonpharmacologic** Therapies, Medication Monitoring, Immunizations, and Imaging. Onel KB, .PMID: 35233961
5. American College of Rheumatology Clinical Guidance for **Multisystem Inflammatory Syndrome** in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022 Apr. PMID: 35118829.
6. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the **interleukin-1 mediated autoinflammatory diseases**: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis. 2022 May. PMID: 35623638.
7. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and **Takayasu Arteritis**. Maz M, Arthritis Rheumatol. 2021 Aug; PMID: 34235884
8. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced **Osteoporosis**, Mary Beth Humphrey, Linda Russell. Pages: 2405-2419 Arthritis Rheumatol 2023 PMID: 37845798
9. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Sammaritano LR et al; Arthritis Rheumatol. 2025 Sep; 77(9): 1115-1135. doi: 10.1002/art.43212. Epub 2025 May 7. PMID: 40331662

EULAR recommendations:

1. EULAR recommendations for the management of **Sjögren's syndrome** with topical and systemic therapies. Ramos-Casals M et al; Ann Rheum Dis. 2020 Jan. PMID: 31672775.
2. EULAR recommendations for the management of systemic **lupus** erythematosus: 2023 update. Fanouriakis A et al; Ann Rheum Dis. 2024 Jan ,PMID: 37827694
3. EULAR/PRES recommendations **for vaccination** of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Jansen MHA et al; Ann Rheum Dis. 2023 Jan. PMID: 35725297
4. EULAR recommendations for the management of **rheumatoid arthritis** with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Smolen JS et al; Ann Rheum Dis. 2023 Jan. PMID: 36357155
5. EULAR recommendations for the management of **ANCA-associated vasculitis**: 2022 update. Hellmich B et al; Ann Rheum Dis. 2024 Jan 2. PMID: 36927642
6. EULAR recommendations for the management of **psoriatic arthritis** with pharmacological therapies : 2023 update. Gossec L et al; Ann Rheum Dis. 2024 May. PMID: 38499325
7. EULAR recommendations for the **non-pharmacological** management of systemic **lupus** erythematosus and **systemic sclerosis**. Parodis I et al; Ann Rheum Dis. 2024 May. PMID: 37433575
8. EULAR recommendations for the use of **imaging in large vessel vasculitis** in clinical practice: 2023 update. Dejaco C et al; Ann Rheum Dis. 2024 May. PMID: 37550004
9. EULAR/PReS recommendations for the diagnosis and management of **Still's disease**, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease Bruno Fautrel et al PMID 39317418

10. EULAR recommendations for the treatment of **systemic sclerosis**: 2023 update Francesco Del Galdo, Ann Rheum Dis. 2025 ; PMID: 39874231
11. EULAR/PReS endorsed recommendations for the management of familial Mediterranean fever (**FMF**): 2024 update. Seza Ozen ET AL; Ann Rheum Dis. 2025 PMID: 40234174
12. EULAR recommendations for use of antirheumatic drugs in **reproduction**, pregnancy, and lactation: 2024 update. Rüegg L et L; Ann Rheum Dis. 2025 Jun; PMID: 40287311

The SHARE initiative recommendations

1. European consensus-based recommendations for diagnosis and treatment of **immunoglobulin A vasculitis**-the SHARE initiative. Rheumatology (Oxford). 2019 Sep. PMID: 30879080